» Articles » PMID: 38363536

GABAergic and Inflammatory Changes in the Frontal Cortex Following Neonatal PCP Plus Isolation Rearing, As a Dual-hit Neurodevelopmental Model for Schizophrenia

Overview
Journal Mol Neurobiol
Date 2024 Feb 16
PMID 38363536
Authors
Affiliations
Soon will be listed here.
Abstract

The pathogenesis of schizophrenia begins in early neurodevelopment and leads to excitatory-inhibitory imbalance. It is therefore essential that preclinical models used to understand disease, select drug targets and evaluate novel therapeutics encompass similar neurochemical deficits. One approach to improved preclinical modelling incorporates dual-hit neurodevelopmental insults, like neonatal administration of phencyclidine (PCP, to disrupt development of glutamatergic circuitry) then post-weaning isolation (Iso, to mimic adolescent social stress). We recently showed that male Lister-hooded rats exposed to PCP-Iso exhibit reduced hippocampal expression of the GABA interneuron marker calbindin. The current study expanded on this by investigating changes to additional populations of GABAergic interneurons in frontal cortical and hippocampal tissue from the same animals (by immunohistochemistry) as well as levels of GABA itself (via ELISA). Because inflammatory changes are also implicated in schizophrenia, we performed additional immunohistochemical evaluations of Iba-1 positive microglia as well as ELISA analysis of IL-6 in the same brain regions. Single-hit isolation-reared and dual-hit PCP-Iso rats both showed reduced parvalbumin immunoreactivity in the prelimbic/infralimbic region of the frontal cortex. However, this was more widespread in PCP-Iso, extending to the medial/ventral and lateral/dorsolateral orbitofrontal cortices. Loss of GABAergic markers was accompanied by increased microglial activation in the medial/ventral orbitofrontal cortices of PCP-Iso, together with frontal cortical IL-6 elevations not seen following single-hit isolation rearing. These findings enhance the face validity of PCP-Iso, and we advocate the use of this preclinical model for future evaluation of novel therapeutics-especially those designed to normalise excitatory-inhibitory imbalance or reduce neuroinflammation.

Citing Articles

Impact of second-generation antipsychotics monotherapy or combined therapy in cytokine, lymphocyte subtype, and thyroid antibodies for schizophrenia: a retrospective study.

Guo X, Kong L, Wen Y, Chen L, Hu S BMC Psychiatry. 2024; 24(1):695.

PMID: 39415112 PMC: 11481721. DOI: 10.1186/s12888-024-06141-z.


Multimorbidity in Severe Mental Illness as Part of the Neurodevelopmental Continuum: Physical Health-Related Endophenotypes of Schizophrenia-A Narrative Review.

Genkel V, Domozhirova E, Malinina E Brain Sci. 2024; 14(7).

PMID: 39061465 PMC: 11274495. DOI: 10.3390/brainsci14070725.

References
1.
Thune J, Uylings H, Pakkenberg B . No deficit in total number of neurons in the prefrontal cortex in schizophrenics. J Psychiatr Res. 2001; 35(1):15-21. DOI: 10.1016/s0022-3956(00)00043-1. View

2.
Ribeiro E, Lima T, Vieira M, Storpirtis S, Aguiar P . Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018; 74(10):1215-1233. DOI: 10.1007/s00228-018-2498-1. View

3.
Kaar S, Nottage J, Angelescu I, Marques T, Howes O . Gamma Oscillations and Potassium Channel Modulation in Schizophrenia: Targeting GABAergic Dysfunction. Clin EEG Neurosci. 2023; 55(2):203-213. PMC: 10851642. DOI: 10.1177/15500594221148643. View

4.
Volk D, Sampson A, Zhang Y, Edelson J, Lewis D . Cortical GABA markers identify a molecular subtype of psychotic and bipolar disorders. Psychol Med. 2016; 46(12):2501-12. PMC: 5584051. DOI: 10.1017/S0033291716001446. View

5.
Chung D, Volk D, Arion D, Zhang Y, Sampson A, Lewis D . Dysregulated ErbB4 Splicing in Schizophrenia: Selective Effects on Parvalbumin Expression. Am J Psychiatry. 2015; 173(1):60-8. PMC: 5242561. DOI: 10.1176/appi.ajp.2015.15020150. View